Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| TherapeuticsMD, Inc.TXMD · Entity 7541 | Director | June 20, 2019 | June 24, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
TherapeuticsMD, Inc.
Report date June 20, 2019 · Filed June 24, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.64 · Expires 2029-06-20 | Direct | 75,000 |
Reported balance
After 2019-06-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-06-20 · Grant · Acquired 75,000 · Balance 75,000 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 20, 2019 Filed Jun 24, 2019 23:03 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 75,000 | $0.00 Strike: $2.64 | $0.00 |
DisclosureSEC source: 0001387131-19-004589 · segal-form4_062019.xml · derivative · entry 1 SEGAL NICHOLAS · CIK 0001543494 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2029-06-20 Read SEC document |
| July 02, 2018 Filed Jul 5, 2018 21:03 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $6.35 | $0.00 |
DisclosureSEC source: 0001387131-18-003031 · segal-form4_070218.xml · derivative · entry 1 SEGAL NICHOLAS · CIK 0001543494 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2028-07-02 Read SEC document |
| June 21, 2017 Filed Jun 23, 2017 20:32 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $5.80 | $0.00 |
DisclosureSEC source: 0001387131-17-003415 · segal-form4_062117.xml · derivative · entry 1 SEGAL NICHOLAS · CIK 0001543494 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2027-06-21 Read SEC document |
| December 21, 2016 Filed Dec 23, 2016 00:09 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $5.68 | $0.00 |
DisclosureSEC source: 0001387131-16-008707 · segal-form4_12212016.xml · derivative · entry 1 SEGAL NICHOLAS · CIK 0001543494 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2026-12-20 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.